年衍药业

Nianyan Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation precision oncology treatments. The company focuses on small molecule inhibitors targeting specific oncogenic drivers such as RET, KRAS, and SHP2. Its lead program, NY-001, is a potent and selective RET inhibitor designed to overcome resistance mutations in patients with RET-fusion positive non-small cell lung cancer and thyroid cancer. Nianyan aims to build a robust pipeline of targeted therapies through its internal R&D capabilities and strategic collaborations. The company is backed by prominent life science investors including Matrix Partners China and Qiming Venture Partners.